Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jul 25, 2017
SOUTH PLAINFIELD, N.J. , July 25, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter financial results and provide an update on the company's business and outlook on Tuesday, August 8, 2017 at
Additional Formats
Jul 24, 2017
SOUTH PLAINFIELD, N.J. , July 24, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Joseph McIntosh , M.D. to Senior Vice President and Head of Clinical Development. Dr. McIntosh will be responsible for all aspects of Clinical Development across PTC's
Additional Formats
Jul 18, 2017
SOUTH PLAINFIELD, N.J. , July 18, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of the results of the ACT DMD trial study ataluren, the only treatment for the underlying cause of nonsense mutation Duchene muscular dystrophy (nmDMD), in the current issue
Additional Formats
Jul 01, 2017
-- RG7916 demonstrated ~400% increase in SMN2 full length/Δ7 mRNA ratio --
-- RG7916 demonstrated a favorable preliminary safety profile and was generally well tolerated in Type 2/3 SMA patients --
Additional Formats
Jun 30, 2017
SOUTH PLAINFIELD, N.J. , June 30, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on June 27, 2017 it approved non-statutory stock options to purchase an aggregate of 74,750 shares of its common stock to seven new employees.
Additional Formats
Jun 22, 2017
SOUTH PLAINFIELD, N.J. , June 22, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of new analyses utilizing alternative methods to understand the progression of Duchenne muscular dystrophy and the benefits of Translarna in nonsense mutation Duchenne
Additional Formats
Jun 06, 2017
- September 28th is FDA's Tentative Date for Advisory Committee Meeting -
Additional Formats
Jun 05, 2017
SOUTH PLAINFIELD, N.J. , June 5, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Marcio Souza to Chief Operating Officer and Christine Utter to Principal Financial Officer and Treasurer. "I am extremely pleased to announce these promotions.
Additional Formats
Jun 02, 2017
SOUTH PLAINFIELD, N.J. , June 2, 2017 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on May 30, 2017 it approved non-statutory stock options to purchase an aggregate of 46,000 shares of its common stock to seven new employees.
Additional Formats
May 23, 2017
- Analysis includes data from ACT DMD on deflazacort and prednisone/prednisolone -
Additional Formats